SCHEMBL18440

SCHEMBL18440

COc1ncccc1CO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
SLC13A5 Q86YT5 1/20 0.49
KDM1A O60341 5/20 0.46
MAOA P21397 2/20 0.46
MAOB P27338 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 2/20 0.44
APLNR P35414 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALOX12 P18054 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31365171 1.00 MEN1 (0.60) MEN1KMT2ASLC13A5KDM1AMAOA
Hydrochloric Acid SCHEMBL5900888 0.98 MEN1 (0.58) MEN1KMT2ASLC13A5KDM1AMAOA
SCHEMBL5780541 0.85 SLC13A5 (0.54) MEN1KMT2ASLC13A5KDM1AMAOA
SCHEMBL16549797 0.83 MEN1 (0.48) MEN1KMT2ASLC13A5L3MBTL1ALDH1A1
SCHEMBL17221232 0.83 MEN1 (0.44) MEN1KMT2ASLC13A5KDM1AMAOA
SCHEMBL3418880 0.82 KMT2A (0.58) MEN1KMT2ASLC13A5L3MBTL1ALDH1A1
SCHEMBL3275439 0.82 MEN1 (0.54) MEN1KMT2AKDM1AL3MBTL1ALDH1A1
SCHEMBL29138536 0.82 SLC13A5 (0.51) MEN1KMT2ASLC13A5KDM1AMAOA
SCHEMBL91503 0.82 SLC13A5 (0.50) MEN1KMT2ASLC13A5KDM1AMAOA
SCHEMBL18291875 0.80 SLC13A5 (0.49) MEN1KMT2ASLC13A5KDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
EP-4153170-B1 MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS SERVIER LAB (FR) 2026-01-21 EP disclosed
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 US disclosed
US-20250376469-A1 INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
US-12486258-B2 Compounds and methods for regulating insulin secretion THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
CN-119677717-A Indolazine derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-03-21 CN disclosed
CN-114026081-B Pyridone derivatives as selective cytotoxic agents against HIV-infected cells 默沙东有限责任公司 2025-02-11 CN disclosed
EP-4499608-A1 INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
EP-4219463-B1 TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN SALUBRIS PHARM CO LTD (CN) 2025-01-15 EP disclosed
US-20240351994-A1 MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS KAERUS BIOSCIENCE LIMITED (GB) 2024-10-24 US disclosed
EP-0786455-B1 IMIDAZOLE DERIVATIVE SHIONOGI & CO (JP) 2003-12-03 EP disclosed
EP-1216980-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME Eisai Co., Ltd. (JP) 2002-06-26 EP disclosed
EP-1165082-A4 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2002-06-12 EP disclosed
US-6358956-B1 IMIDAZOLYLALKYL-1-PIPERAZINE DERIVATIVES; FARNESYL-PROTEIN AND GERANYLGERANYL TRANSFERASE INHIBITORS; ANTICARCINOGENIC AGENTS MERCK & CO., INC. 2002-03-19 US disclosed
EP-1165082-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2002-01-02 EP disclosed
US-6147097-A METHOD FOR TREATING AIDS SHIONOGI & CO., LTD. (JP) 2000-11-14 US disclosed
WO-2000051611-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-09-08 WO disclosed
US-5910506-A IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC SHIONOGI & CO., LTD. (JP) 1999-06-08 US disclosed
EP-0786455-A1 IMIDAZOLE DERIVATIVE SHIONOGI & CO., LTD. (JP) 1997-07-30 EP disclosed
EP-0284174-A1 Therapeutic preparations IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351994-A1 MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X ASSOCIATED DISORDERS KCNN2, KCNN1, KCNJ11 MEN1 596/4885KMT2A 790/4885SLC13A5 546/4885
US-12486258-B2 Compounds and methods for regulating insulin secretion IAPP, GPR119, PNLIP MEN1 2917/4885KMT2A 4819/4885SLC13A5 3089/4885
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer ADORA1, ADORA3, OPRL1 MEN1 3935/4885KMT2A 3358/4885SLC13A5 736/4885
US-20250376469-A1 INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM4, TRPM2 MEN1 1648/4885KMT2A 2699/4885SLC13A5 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.